Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + pertussis + tetanus vaccine
- Development stage
- Unknown
- Lead developer
- Abdul Latif Jameel Poverty Action Lab
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria + pertussis + tetanus (DPT) vaccine is a trivalent combination biological product used for active immunization against three serious bacterial diseases: diphtheria, pertussis (whooping cough), and tetanus. It consists of diphtheria and tetanus toxoids—detoxified bacterial toxins that induce the production of neutralizing antibodies—and pertussis antigens, which can be either inactivated whole-cell Bordetella pertussis (DTwP) or acellular components (DTaP) such as pertussis toxoid and filamentous hemagglutinin. The vaccine is a fundamental part of the WHO/UNICEF Expanded Programme on Immunization (EPI) and is typically administered to infants in a multi-dose series. In a cluster-randomized trial conducted in rural Rajasthan, India, by the Abdul Latif Jameel Poverty Action Lab (J-PAL) and the Massachusetts Institute of Technology (MIT), the vaccine was used to study the impact of reliable outreach camps and non-cash incentives on childhood immunization rates.
- Brand names
- Tripedia
- Other names
- DTP vaccineDPT vaccinetriple vaccinediphtheria-tetanus-pertussis vaccine
02
Targets
BCR (Naïve B-cell receptors specific for diphtheria toxoid, tetanus toxoid, and pertussis antigens)PRR (Pattern recognition receptors)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on diphtheria + pertussis + tetanus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + pertussis + tetanus vaccine.